

Timing to Intubation COVID-19 Patients: Can We Put It Off Until Tomorrow?

Julio Cesar Garcia de Alencar (✉ julio.alencar@hc.fm.usp.br)

Universidade de Sao Paulo <https://orcid.org/0000-0001-5859-6060>

Juliana Martes Sternlicht

USP: Universidade de Sao Paulo

Alicia Dudy Muller Veiga

USP: Universidade de Sao Paulo

Julio Flávio Meirelles Marchini

USP: Universidade de Sao Paulo

Juliana Carvalho Ferreira

USP: Universidade de Sao Paulo

Carlos Roberto Ribeiro Carvalho

USP: Universidade de Sao Paulo

Izabel Marcilio

USP: Universidade de Sao Paulo

Katia Regina Silva

USP: Universidade de Sao Paulo

Vilson Cobello Junior

USP: Universidade de Sao Paulo

Marcelo Consorti Felix

USP: Universidade de Sao Paulo

Luz Marina Gomez Gomez

USP: Universidade de Sao Paulo

Heraldo Possolo Souza

USP: Universidade de Sao Paulo

Denis Deratani Mauá

USP: Universidade de Sao Paulo

Emergency USP COVID Group

USP: Universidade de Sao Paulo

HCFMUSP COVID-19 Study Group

USP: Universidade de Sao Paulo

Keywords: COVID-19, Intubation, Emergency medicine

Posted Date: July 26th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-710990/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Healthcare on January 21st, 2022. See the published version at <https://doi.org/10.3390/healthcare10020206>.

Abstract

Background: The decision to intubate COVID-19 patients receiving non-invasive respiratory support is challenging, requiring a fine balance between early intubation and risks of invasive mechanical ventilation versus the adverse effects of delaying intubation. This present study analyzes the relationship between intubation day and mortality in COVID-19 patients.

Methods: We performed a unicentric retrospective cohort study considering all adult laboratory-confirmed SARS-CoV-2 infection consecutively admitted at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil, between March 2020 and August 2020 requiring invasive mechanical ventilation. The primary outcome was all-cause mortality within 28 days after intubation, and a Cox model was used to evaluate the effect of time from onset of symptoms to intubation in mortality

Results: A total of 592 (20%) adult consecutive patients out of 3020 admitted with COVID-19 were intubated during the study period. The median time from admission to intubation was one day (interquartile range, 0-3), and 310 patients (52%) who were intubated and mechanically ventilated deceased 28 days after intubation. Each additional day between the onset of symptoms and intubation was significantly associated with higher in-hospital death (adjusted hazard ratio, 1.018; 95% CI, 1.005-1.03).

Conclusion: Among patients infected with SARS-CoV-2 who were intubated and mechanically ventilated, delaying intubation in the course of symptoms may be associated with higher mortality.

Trial registration: The study protocol was approved by the local Ethics Committee (opinion number 3.990.817; CAAE: 30417520.0.0000.0068).

Background

Patients with severe COVID-19 present with dyspnea and hypoxemia [1]. A portion of these patients may develop Acute Respiratory Distress Syndrome (ARDS), which is defined as the acute onset of bilateral infiltrates, severe hypoxemia, and lung edema that is not fully explained by cardiac failure or fluid overload [2]. Therapeutic strategies for these patients require respiratory support, ranging from supplementary oxygen through nasal cannula, non-rebreather mask, high-flow nasal oxygen cannula (HFNO), and non-invasive ventilation (NIV) to endotracheal intubation (ETI) and invasive mechanical ventilation (MV) [3].

Several guidelines have advocated early ETI and MV in the management of COVID-19-related ARDS. These guidelines stated that ETI and MV must be established as soon as non-invasive respiratory interventions fail to maintain O₂ saturation (SpO₂) above 90% or to reduce inspiratory effort [4–6]. Moreover, postponed intubation may increase the risk of peri-procedural cardiac arrest, whether the delay results in worsened hypoxemia and lack of preoxygenation [7–9].

Regardless of the definition of early or late intubation (i.e., based on a specific time threshold from the onset of symptoms, ICU admission, or of a prior trial of HFNO/NIV), clinicians caring for patients with COVID-19 seem to become eager to favor a wait-and-see strategy over time, tolerating the use of non-invasive oxygen support and lower SpO₂ for more extended periods [10]. After all, MV hold several risks, such as ventilation-associated pneumonia and septic shock, dysfunction and atrophy of respiratory muscles, and hemodynamic complications related to positive pressure and sedation [11–13]. Beyond that, COVID-19 patients submitted to ETI usually received non-invasive respiratory support prior to procedure, and some studies showed that HFNO and NIV might prevent intubation in COVID-19 patients, leading to reduce mortality or, at least, to lower demand for mechanical ventilators in this pandemic moment [14].

Therefore, physicians must carefully consider the decision to submit these patients to ETI and MV. Early intubation may expose patients to the risks of MV complications. On the other hand, delaying intubation might worsen their respiratory condition, even to a non-returning point [15]. Our knowledge about the exact moment to indicate ETI and MV for COVID-19 patients is still incomplete; however, it is known that in other diseases that develop with respiratory failure, with or without ARDS, delaying intubation leads to worse outcomes when compared to intubation at the time of admission to Intensive Care Unit (ICU) or diagnosis of ARDS [16,17].

Considering that there is no consensus about the best moment to indicate endotracheal intubation and mechanical ventilation for severe COVID-19 patients in respiratory failure, we performed a retrospective analysis of these patients to determine the association between time of intubation during the disease evolution and outcomes.

Methods

2.1 The aim, design and setting of the study

We conducted a retrospective unicentric cohort study from March to August 2020 at Emergency Department (ED) in Hospital das Clínicas da Universidade de São Paulo (HC-FMUSP), a 2200-bed urban, academic medical center comprising five institutes and two auxiliary hospitals. During the pandemic, the HC-FMUSP isolated its largest Institute with 900 beds for COVID-19 patients and designated ED for the reception and care of patients with severe COVID-19.

We included all consecutive adult patients (≥ 18 years) with confirmed COVID-19 and mechanical invasive ventilation requirements. Confirmed COVID-19 was defined as at least one positive result on reverse transcriptase-polymerase chain reaction (RT-PCR) obtained from nasopharyngeal swabs or bronchial secretions.

We excluded patients already intubated at admission, patients with Hospital-Acquired SARS-CoV-2 infection, defined as date of hospitalization before the onset of symptoms, and patients with missing dates.

There were no established protocols or predefined criteria for intubation in our institution. The decision to intubate has been left to the discretion of the Emergency Physicians or Intensivists who responded in accordance with patients' individual needs and clinical status. Most of the clinicians practiced early intubation strategy during the beginning of the pandemic. However, as more data emerged and recommendations changed, clinicians were more comfortable monitoring patients on noninvasive modes of oxygenation (such as HFNO or NIV). Nowadays, the clinician's judgment to initiate mechanical ventilation was influenced by a multitude of factors, including oxygen saturation, respiratory rate, work of breathing, mental status, and hemodynamics.

The study protocol was approved by the local Ethics Committee (opinion number 3.990.817; CAAE: 30417520.0.0000.0068), which also waived the need for written informed consent. We adhere to STROBE guidelines.

2.2 Study Protocol and Outcomes

Patient data were collected through electronic medical records, and a database was built on REDCap[®] software (Vanderbilt University). The variables studied were sex, age, COVID-19 RT-PCR results, date of admission, date of symptoms, SpO₂ at admission, date of intubation, and outcomes (death or discharge).

The primary outcome was all-cause mortality within 28 days after intubation.

2.3 Statistical Analysis

Continuous data were described as means and standard deviations (SDs) when the distribution is normal and medians and interquartile ranges (IQRs) for non-normally distributed data. Categorical variables are described as the number of events and proportions.

T-tests were used to compare variables with normal distribution; Wilcoxon rank-sum tests, for comparisons of non-normally distributed continuous variables; and Chi-square tests, for comparisons of categorical variables.

For the primary outcome analysis, we present a Kaplan-Meier survival plot for the univariate analysis, along with an unadjusted Cox model to examine the relationship between the day of intubation (counting from the onset of symptoms) and 28-day mortality after the ETI. We then fit a multivariable Cox model adjusting for age, sex, the number of comorbidities, respiratory rate at admission, peripheral oxygen saturation on room air at admission, serum urea at admission, and C-reactive protein levels at admission and the time (in days) after the covid symptoms first appeared until the day of the intubation. These variables make up the 4C score [18]. We had demonstrated that 4C score was an accurate predictor of outcomes in our population [19]. In this present study, we did not have access to the Glasgow coma scale, and we did not use this variable for adjusted analyzes.

We evaluated the proportional hazards assumption with Schöenfeld residuals and log-log plots. Effect estimates from the Cox models are presented as hazard ratios.

Moreover, we also performed a multivariable logistic regression model to examine the relationship between individual baseline characteristics (using 4C variables at admission) and outcomes. Multivariable models were then created to investigate the association between the day of intubation and mortality 28-days after the procedure after adjusting for differences in patients at admission.

Two expert mathematicians (LMGG and DDM) performed this data analysis. For all analyses, the null hypothesis was evaluated at a two-sided significance level of 0.05, with the calculation of 95% confidence intervals.

Statistical analyses were performed using StataCorp® 2013 and using R version 4.0.3.

Results

3.1. Patients

Our hospital was designated to be the reference for severe COVID-19 cases during the pandemics. A total of 3020 consecutive COVID-19 patients were admitted during the study period, all of them classified as critically ill, according to WHO guidelines [4]. For our analysis, we evaluated all 592 patients with Severe Acute Respiratory Syndrome caused by SARS-CoV-2 virus who were submitted to EIT and MV in our institution (Figure 1).

All these 592 patients were treated in ICU, under the institution protocol. Mortality after 28 days was high in this group (52.4%) and non survivors were older and had more comorbidities than survivors, as observed in Table 1. Other severity markers were low lymphocytes, low platelet count and impaired renal function at admission.

3.2. Timing of intubation and mortality

The median time from onset of symptoms to intubation was 9 days (IQR 7-14). For each additional day between the onset of symptoms and intubation, the unadjusted hazard ratio for death within the follow-up period was 1.006 (95% CI, 1.006-1.030) (Figure 2).

We performed a multivariable Cox model adjusting in 530 patients, because 62 (11.6%) observations were excluded again due to missing data. Among these, 272 patients died. After adjustment for all covariates, the hazard ratio was 1.018 (95% CI, 1.018-1.03) (Figure 3).

According to the COX analysis, multivariate logistic regression adjusted by 4C score at admission demonstrated a statistically significant relationship between the day of intubation and mortality with an increase of OR 1.04 per day. The effect of time to intubation on 28-day mortality was 0.0076 [95% CI 0.001-0.014], which indicates an average increase of 0.8% in the probability of death per day.

Lastly, we performed a post-hoc exploratory analysis using COX proportional hazard regression model adjustment for 4C variables and SAPS 3 at admission, and the hazard ratio was 1.015 (95% CI, 1.01 1.025). (Table 2)

Discussion

Choosing the exact moment to submit a COVID-19 patient in respiratory distress to endotracheal intubation and mechanical ventilation is still a challenge to emergency physicians and intensivists. In this cohort study, we show that timing of intubation affects the outcome, and the adjusted hazard ratio for mortality was 1.018 for each day of delay in intubation following the onset of symptoms.

For our analysis, we excluded patients admitted already intubated, since we could not be assured about the conditions before the procedure. We also excluded patients with Hospital-Acquired SARS-CoV-2 because we assumed that ETI should be related to other conditions. Consequently, our final sample consisted of 592 subjects.

Initially, we characterized these patients and observed several differences between the survivors and non survivors. These differences have been described before by us and other groups [20–23]. Predictors of unfavorable outcomes in our sample were older age, the number of previous diseases, lymphopenia, and impaired renal function.

The main finding of this work is that delaying intubation in patients with respiratory failure by COVID-19 pneumonia may lead to deleterious effects. These results are in accordance with reports about timing of intubation in patients with ARDS of other etiologies. In ICU patients that met ARDS criteria, the ones that were submitted to mechanical ventilation later presented higher 60-day mortality compared to patients who were intubated at the moment of ARDS diagnosis [17]. Interestingly, patients with early intubation were sicker at the time of ARDS diagnosis, as demonstrated by higher APACHE II scores when compared with the late-intubation subgroup, suggesting that delaying mechanical ventilation was the responsible for the unfavorable outcomes [17].

In a very influential editorial, published at the pandemics first months, it was advocated early ETI and MV for COVID-19 ARDS [24]. The authors reasoned that the spontaneous vigorous inspiratory effort produced by these patients could lead to increased high transpulmonary pressures and consequent lung damage. This hypothesis was challenged soon after [25] and the issue is still unsolved. A recent meta-analysis evaluated 12 studies and could not find evidence that timing of intubation have any effect in outcomes [10]; however, the included studies were heterogeneous and a definitive conclusion could not be reached. Moreover, all the studies enrolled patients at ICUs and some of them had very few patients in each arm.

Our data present a clear distinction between patients who were submitted to ETI and MV as soon as the respiratory failure were made and the ones who were submitted to the procedures later. The Kaplan-Meier

curves show an increase in death probability each day the ETI is delayed. This finding was maintained even when all the corrections were performed to exclude confounding factors.

There are some possible explanations for these findings. First, and most important, the data presented here are from the first year of pandemics. It was not clear the best moment to perform ETI in COVID-19 patients and our institution did not have a policy about it at that time. Second, we need to point out the fear of serious complications during ETI. Although we have shown the safety of the procedure in COVID-19 [26], there was still the idea that keeping the patients out of mechanical ventilation would be safer. There was, also, the track record of the intubated patients in our country. COVID-19 patients requiring MV have had an unacceptable mortality in Brazil [21] and, although our hospital was better prepared for the pandemics than the rest of our country, the idea that patients in mechanical ventilation had a higher risk of death could have entered doctors' minds. Finally, it is possible that patients who were submitted to delayed intubation were the ones more severely ill, and the procedure was postponed due to the patients' worsening condition. For example, ETI could be delayed because the patient was hemodynamic unstable and would not tolerate sedation and positive pressure. This is less probable, since the ICU time after intubation was similar between the two groups.

This work has some limitations, and these data must be interpreted with caution. First, given the retrospective nature of this study, we are unable to determine whether delayed intubation itself resulted in the observed increase in mortality. It is possible that the procedure postponement resulted in fewer intubated patients overall, leaving only the most severely ill patients in the cohort receiving mechanical ventilation. We reduced this bias by performing an analysis adjusted by the 4C score on admission. Second, we could not determine the factors that influenced the clinicians' decision regarding the timing of intubation with this study design. And, finally, the retrospective data used was not sufficiently granular to examine the impact of pharmacologic therapies prior to versus after intubation.

On the other hand, this study has some very important strengths. It was conducted at the Emergency Department, and not only in ICUs. The number of patients enrolled is higher than most of the studies approaching this issue. The fact that it was performed in a single center is more a strength than a weakness. Our hospital was dedicated to assist only severe COVID-19 patients. At the pandemics peak, we had 350 ICU beds for these patients. It allows us to assure that the institution guidelines were followed in every patient, the patients received the same type of care, with no difference in medication or ventilation parameters. Moreover, all the medical personnel in ICUs were certified intensivists, with a long training in attending patients with respiratory failure. The track record of our ICUs were comparable to other centers around the world [27], confirming that the ICU care was not determinant for the outcome.

Besides those factors, the adjusted analyzes using 4C at admission were performed by two mathematicians using the COX model and logistic regression. Data demonstrated the association between the day of intubation and mortality risk. Finally, contrary to other works about the issue, we counted the timing of intubation based on the start of the symptoms and not on the day of admission, what brings more weight to our findings.

Conclusions

This combination of findings provides some support for the conceptual premise that increasing the time from onset of symptoms to intubation in severe COVID-19 patients is associated with higher mortality. Some of the issues emerging from this finding relate specifically to supportive care consisting of early intubation may be associated with better outcomes.

Abbreviations

ARDS - Acute respiratory distress syndrome

ETI - Endotracheal intubation

HFNO - High-flow nasal oxygen cannula

ICU – Intensive Care Unit

IQR - Interquartile ranges

MV - Invasive mechanical ventilation

NIV - Non-invasive ventilation

Rt-PCR - Reverse transcriptase-polymerase chain reaction

SD - Standard deviations

SpO₂ - O₂ saturation

Declarations

ETHICAL APPROVAL AND CONSENT TO PARTICIPATE

The study protocol was approved by the local Ethics Committee (CAPpesq, number 3.990.817; CAAE: 30417520.0.0000.0068), which also waived the need for written informed consent.

CONSENT FOR PUBLICATION

All authors have read and approved the submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language.

AVAILABILITY OF SUPPORTING DATA

The data that support the findings of this study are available from the corresponding author JCGA upon reasonable request.

COMPETING INTERESTS

The authors declare they have no conflicts of interest.

FUNDING

This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), grants #2020/04.738-8 and #2016/14.566-4.

AUTHORS' CONTRIBUTIONS

JCGA, JMS, HPS conceived of the presented idea. ADM, JCF, JEP, MCF, IOMS, KRS, VSJ, RKS designed the model and the computational framework. LMGG and DDM performed the numerical calculations and analyzed the data. CRRG and HPS supervised the project. JCGA and JMS A.B., B.C. and C.D. wrote the paper with input from all authors.

ACKNOWLEDGEMENTS

This research was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).

Emergency USP COVID-19 Group:

Gabriel Martínez, Giovanna Babikian Costa, Renan Dourado Tínel. Henrique Tibucheski dos Santos, Edwin Albert D'Souza, Bianca Ruiz Nicolao, Stéfany Franhan Barbosa de Souza, João Martelleto Baptista, Natalia Paula Cardoso, Bruna Tolentino Caldeira, Gabriel Travessini, Rafael Berenguer Luna, João Pedro Afonso Nascimento, Ligia Trombetta Lima, Willaby Serafim Cassa Ferreira, Alexandre Lemos Bortolotto, Ademar Lima Simões, Rodrigo Cezar Mileo, Manuela Cristina Adsuara Pandolfi, Mariana Mendes Gonçalves Cimatti De Calasans, Vitor Macedo Brito Medeiros, Osvaldo Santistevan Claire, Thiago Areas Lisboa Netto, Juliana Batista Rodrigues Pereira, Rodrigo Werner Toccoli, Carlos Eduardo Umehara Juck, Everton Luis Santos Moreira, Rodrigo de Souza Abreu, Maria Lorraine Silva de Rosa, Leonardo Antonio Coimbra Moreira, Pedro Antonio Araújo Simões, Isabela Harumi Otori, Matheus Finardi Lima de Faria, Nilo Arthur Bezerra Martins, Tales Cabral Monsalvarga, Marcelo de Oliveira Silva, Luiza Boscolo, Clara Carvalho de Alves Pereira, Diego Juniti Takamune, Millena Gomes Pinheiro Costa, Gabriel de Paula Maroni Escudeiro, Arthur Petrillo Bellintani, Diogo Visconti Guidotte, Débora Lopes Emerenciano, João Vitor Ziroldo Lopes, Erika Thiemy Brito Miyaguchi, Marcelo Petrof Sanches, Bruno Marques, Felipe Mouzo Bortoleto, Angélica Saiuri de Aurélio Penteado, Danilo Dias De Francesco, Luca Suzano Baptista, Mário Turolla Ribeiro, Matheus Zanelatto Junqueira, Matheus Nakao de Sousa, Mônica Yhasmin de Lima Redondo, Isabela Argollo Ferreira, Joana Margarida Alves Mota, Thalissa Ferreira, Diego Vinicius Santinelli Pestana, Maria Clara Saad Menezes, Helena Souza Pinto, Isabelly Victoria Simoes Melchiori, Lucas de Mello Queiroz, Pollyana Karine Lopes dos Santos, Marco Antonio Rodrigues e Mello, Gustavo Henrique Mori, Laura Fernandes Berto, Luiza Maria Goldstein Rubio, Marcia Harumy Yoshikawa, Amanda Dafne Zara, Gabriel Kenji Ito

References

1. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. Solomon CG. editor. *N Engl J Med*. 2020;383:2451–60. doi:10.1056/NEJMcp2009575.
2. ARDS Definition Task Force. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012;307: 2526–33. doi:10.1001/jama.2012.5669.
3. Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. *JAMA*. 2018;319:698. doi:10.1001/jama.2017.21907.
4. WHO, World Health Organization. Clinical Management of Covid-19—Interim Guidance. 2021 [cited 7 May 2021]. Available: <https://www.who.int/publications/i/item/clinical-management-of-covid-19>.
5. Brown CA, Mosier JM, Carlson JN, Gibbs MA. Pragmatic recommendations for intubating critically ill patients with suspected COVID-19. *J Am Coll Emerg Physicians Open*. 2020;1:80–4. doi:10.1002/emp2.12063.
6. Cook TM, El-Boghdady K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID -19: Guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetists. *Anaesthesia*. 2020;75:785–99. doi:10.1111/anae.15054.
7. April MD, Arana A, Reynolds JC, Carlson JN, Davis WT, Schauer SG, et al. Peri-intubation cardiac arrest in the Emergency Department: A National Emergency Airway Registry (NEAR) study. *Resuscitation*. 2021;162:403–11. doi:10.1016/j.resuscitation.2021.02.039.
8. De Jong A, Rolle A, Molinari N, Paugam-Burtz C, Constantin J-M, Lefrant J-Y, et al. Cardiac Arrest and Mortality Related to Intubation Procedure in Critically Ill Adult Patients: A Multicenter Cohort Study. *Crit Care Med*. 2018;46:532–9. doi:10.1097/CCM.0000000000002925.
9. Heffner AC, Swords DS, Neale MN, Jones AE. Incidence and factors associated with cardiac arrest complicating emergency airway management. *Resuscitation*. 2013;84:1500–4. doi:10.1016/j.resuscitation.2013.07.022.
10. Papoutsis E, Giannakoulis VG, Xourgia E, Routsis C, Kotanidou A, Siempos II. Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of non-randomized cohort studies. *Crit Care*. 2021;25:121. doi:10.1186/s13054-021-03540-6.
11. Pham T, Brochard LJ, Slutsky AS. Mechanical Ventilation: State of the Art. *Mayo Clin Proc*. 2017;92: 1382–1400. doi:10.1016/j.mayocp.2017.05.004.
12. Roedel K, Jarczak D, Thasler L, Bachmann M, Schulte F, Bein B, et al. Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany. *Aust Crit Care*. 2021;34:167–75. doi:10.1016/j.aucc.2020.10.009.
13. Pun BT, Badenes R, Heras La Calle G, Orun OM, Chen W, Raman R, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. *Lancet*

- Respir Med. 2021;9:239–50. doi:10.1016/S2213-2600(20)30552-X.
14. Ashish A, Unsworth A, Martindale J, Sundar R, Kavuri K, Sedda L, et al. CPAP management of COVID-19 respiratory failure: a first quantitative analysis from an inpatient service evaluation. *BMJ Open Respir Res.* 2020;7:e000692. doi:10.1136/bmjresp-2020-000692.
 15. Nasa P, Azoulay E, Khanna AK, Jain R, Gupta S, Javeri Y, et al. Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. *Crit Care.* 2021;25:106. doi:10.1186/s13054-021-03491-y.
 16. Bauer PR, Kumbamu A, Wilson ME, Pannu JK, Egginton JS, Kashyap R, et al. Timing of Intubation in Acute Respiratory Failure Associated With Sepsis: A Mixed Methods Study. *Mayo Clin Proc.* 2017;92:1502–1510. doi:10.1016/j.mayocp.2017.07.001.
 17. Kangelaris KN, Ware LB, Wang CY, Janz DR, Zhuo H, Matthay MA, et al. Timing of Intubation and Clinical Outcomes in Adults With Acute Respiratory Distress Syndrome*. *Crit Care Med.* 2016;44:120–9. doi:10.1097/CCM.0000000000001359.
 18. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. *BMJ.* 2020; m3339. doi:10.1136/bmj.m3339.
 19. Lazar Neto F, Marino LO, Torres A, Cilloniz C, Meirelles Marchini JF, Garcia de Alencar JC, et al. Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.* 2021;S1198-743X(21):00136–1. doi:10.1016/j.cmi.2021.03.002.
 20. Brandão Neto RA, Marchini JF, Marino LO, Alencar JCG, Lazar Neto F, Ribeiro S, et al. Mortality and other outcomes of patients with coronavirus disease pneumonia admitted to the emergency department: A prospective observational Brazilian study. *PLoS One.* 2021;16:e0244532. doi:10.1371/journal.pone.0244532.
 21. Ranzani OT, Bastos LSL, Gelli JGM, Marchesi JF, Baião F, Hamacher S, et al. Characterisation of the first 250+000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. *Lancet Respir Med.* 2021. doi:10.1016/S2213-2600(20)30560-9.
 22. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ.* 2020;369:m1985. doi:10.1136/bmj.m1985.
 23. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* 2020;323:1239–42. doi:10.1001/jama.2020.2648.
 24. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. *JAMA.* 2020;323:2329. doi:10.1001/jama.2020.6825.
 25. Tobin MJ, Laghi F, Jubran A. Caution about early intubation and mechanical ventilation in COVID-19. *Ann Intensive Care.* 2020;10:78. doi:10.1186/s13613-020-00692-6.

26. de Alencar JCG, Marques B, Marchini JFM, Marino LO, Ribeiro SC da Bueno C CG, et al. First-attempt intubation success and complications in patients with COVID-19 undergoing emergency intubation. *J Am Coll Emerg Physicians Open*. 2020. doi:10.1002/emp2.12219.
27. Ferreira JC, Ho Y-L, Besen BAMP, Malbouisson LMS, Taniguchi LU, Mendes PV, et al. Protective ventilation and outcomes of critically ill patients with COVID-19: a cohort study. *Ann Intensive Care*. 2021;11:92. doi:10.1186/s13613-021-00882-w.

Tables

Table 1. Baseline Characteristics According to Outcomes

Sample Characteristic	Survivors	Non survivors	p value*
Sample size (n)	282	310	-
Age, y	56.8 (44.9-65.6)	64.8 (55.8-72.3)	<0.001
Sex (male)	132 (22.3)	214 (36.1)	<0.001
Status at admission			
Respiratory rate, breaths/min	26 (22-32)	25 (20-30)	0.09
Oxygen saturation, %	93 (90-95)	93 (89-96)	0.63
Heart rate, beats/min	90 (80-101)	92 (80.3-101)	0.40
SAPS 3	61 (50-70.5)	67 (54.5-77)	< 0.001
Blood tests			
Leucocytes, thousand per mm³	9.0 (6.9-12.4)	8.8 (5.9-12.5)	0.27
Lymphocytes, thousand per mm³	0.9 (0.7-1.2)	0.7 (0.5-1.1)	<0.001
Platelets, thousand per mm³	222 (173.8-294.3)	195 (140.5-262)	<0.001
Creatinine, mg/dL	0.9 (0.7-1.4)	1.1 (0.8-2.0)	<0.001
Urea, mg/dL	38 (25-59)	53 (35-84)	<0.001
C-reactive protein, mg/dL	182.7 (104.1-281.8)	168.8 (94.1-256.7)	0.24
D-dimer, µg/mL	1531 (876.8-4551)	1692 (964-5485)	0.39
Lactate dehydrogenase, U/L	483 (359.8-611.5)	519 (390.3-673.3)	0.04
Comorbidities, n (%)			
Hypertension	139 (23.5)	226 (38.2)	<0.001
Diabetes	92 (15.5)	148 (25.0)	<0.001
Dialysis	59 (10.0)	174 (29.4)	<0.001
Cancer	8 (1.4)	43 (7.3)	<0.001
Immunodeficiency	7 (3.0)	15 (6.3)	<0.001
Current smoker	22 (3.7)	40 (6.8)	<0.001
Obesity	89 (15.3)	81 (14.0)	<0.001

Table 2. Hazard ratio multivariable Cox mode

	Hazard Ratio	p-value	95% CI for the Hazard Ratio	
Sex (male)	1,235	0,111	0,953	1,601
Age, yr	1,018	0,001	1,007	1,028
C-reactive protein, mg/dL	0,998	0,010	0,997	1,000
Respiratory rate, breaths/min	0,983	0,076	0,965	1,002
Oxygen saturation, %	0,992	0,339	0,976	1,008
Urea, mg/dL	1,005	0,000	1,003	1,008
Days since symptoms	1,022	0,000	1,010	1,034
SAPS 3	1,015	0,002	1,005	1,025

Figures




Figure 1

Study cohort.




Figure 2

Kaplan-Meier survival plot for 28-days mortality in relation to intubation time




Figure 3

Kaplan-Meier survival plot for 28-days mortality in relation to intubation time after 4C score at admission adjustments